Wolverine Trading, LLC Seagen Inc. Call Options Transaction History

Wolverine Trading, LLC

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2023 Nov 15, 2023	SELL	$191.51 - $216.16 $57,453 - $64,848	-300 Reduced 5.26%	5,400 $1.15 Million
Q2 2023 Aug 23, 2023	SELL	$187.64 - $206.25 $1.07 Million - $1.18 Million	-5,700 Reduced 50.0%	5,700 $1.1 Million
Q1 2023 May 15, 2023	BUY	$127.59 - $203.08 $944,166 - $1.5 Million	7,400 Added 185.0%	11,400 $2.32 Million
Q4 2022 Feb 14, 2023	SELL	$117.37 - $139.17 $2.09 Million - $2.48 Million	-17,800 Reduced 81.65%	4,000 $514,000
Q3 2022 Nov 14, 2022	BUY	$135.27 - $180.11 $1.54 Million - $2.05 Million	11,400 Added 109.62%	21,800 $2.96 Million
Q2 2022 Aug 15, 2022	BUY	$108.81 - $179.33 $598,455 - $986,315	5,500 Added 112.24%	10,400 $1.86 Million
Q4 2021 Feb 14, 2022	SELL	$142.57 - $190.86 $2.62 Million - $3.51 Million	-18,400 Reduced 78.97%	4,900 $770,000
Q3 2021 Nov 12, 2021	BUY	$142.45 - $169.82 $2.89 Million - $3.45 Million	20,300 Added 676.67%	23,300 $3.83 Million
Q2 2021 Aug 06, 2021	SELL	$135.08 - $161.1 $634,876 - $757,170	-4,700 Reduced 61.04%	3,000 $476,000
Q1 2021 May 14, 2021	SELL	$137.51 - $190.8 $1.49 Million - $2.06 Million	-10,800 Reduced 58.38%	7,700 $1.06 Million
Q4 2020 Feb 12, 2021	BUY	$164.63 - $211.93 $3.05 Million - $3.92 Million	18,500 New	18,500 $3.4 Million

1.26M

23K

55.2K

Ticker SGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,664,992
Description
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company offers ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas; PADCEV, an ADC targeting Nectin-4 for the treatment ...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.